Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:198 |
|---|---|
| Enthalten in: |
British journal of haematology - 198(2022), 5 vom: 01. Sept., Seite 826-829 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shafat, Tali [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-CD20 monoclonal antibodies |
|---|
| Anmerkungen: |
Date Completed 23.08.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.18315 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342397257 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342397257 | ||
| 003 | DE-627 | ||
| 005 | 20231226014023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.18315 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342397257 | ||
| 035 | |a (NLM)35718461 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shafat, Tali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.08.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Haematological malignancies | |
| 650 | 4 | |a SARS-CoV-2 infection | |
| 650 | 4 | |a anti-CD20 monoclonal antibodies | |
| 650 | 4 | |a obinutuzumab | |
| 650 | 4 | |a rituximab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a obinutuzumab |2 NLM | |
| 650 | 7 | |a O43472U9X8 |2 NLM | |
| 700 | 1 | |a Grupel, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Porges, Tzvika |e verfasserin |4 aut | |
| 700 | 1 | |a Levi, Itai |e verfasserin |4 aut | |
| 700 | 1 | |a Yagel, Yael |e verfasserin |4 aut | |
| 700 | 1 | |a Nesher, Lior |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 198(2022), 5 vom: 01. Sept., Seite 826-829 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:198 |g year:2022 |g number:5 |g day:01 |g month:09 |g pages:826-829 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.18315 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 198 |j 2022 |e 5 |b 01 |c 09 |h 826-829 | ||